Previous 10 | Next 10 |
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has entered into definitive agreements with several institutional and accredited investors for th...
Thinly traded nano cap Novus Therapeutics ( NVUS -28.1% ) slumps on more than a 5x surge in volume, albeit on turnover of only 145K shares, in response to results from two Phase 1 studies evaluating lead candidate OP0201. More news on: Novus Therapeutics, Inc., Healthcare stocks news, ...
OP0201 Was Safe and Well-Tolerated in Healthy Adults and Adults with Acute Otitis Media Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced results ...
Novus Therapeutics (NASDAQ: NVUS ): Q4 GAAP EPS of -$0.49 misses by $0.09 . Cash and cash equivalents of $12.97M Press Release More news on: Novus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter and year ended December 31, 2018 and provided updates on the OP0201 dev...
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate at the 8th Annual SVB Leerink Healthcare Conference on Thursday, Februa...
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first patients in a phase 2a trial of OP0201, the company’s lead product can...
Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indic...
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult subjects in study C-001, a phase 1 pharmacodynamics clinical trial of O...
Gainers: Maxwell Technologies (NASDAQ: MXWL ) +50% . Therapix Biosciences (NASDAQ: TRPX ) +24% . Continental Materials (NYSEMKT: CUO ) +24% . PHI (NASDAQ: PHII ) +22% . Orgenesis (NASDAQ: ORGS ) +19% . The Ultimate Software Group (NASDAQ: ULTI ) +20% . Aileron Therapeutics (NASDAQ: ...
News, Short Squeeze, Breakout and More Instantly...
Novus Therapeutics Inc. Company Name:
NVUS Stock Symbol:
NASDAQ Market:
Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021 Eledon is well financed to complete up to four Phase 2 clinical trials of lead candidate AT-1501, a potential best in class anti-CD40L monoclonal antibody ...
IRVINE, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those l...
Former Chief Development and Chief Operating Officer of MyoKardia, Inc. brings extensive clinical development expertise as Novus prepares to conduct up to four Phase 2 clinical trials Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharma...